Role of PSMA in Aberrant Cell Cycle Progression in Prostate Cancer
Abstract
PSMA, a transmembrane glycoprotein of approximately 100kD, is expressed in prostate epithelial cells (Horoszewicz et al., 1987; Israeli et al., 1993). In addition to being expressed in non-neoplastic prostate epithelium, PSMA is expressed by a very high proportion of prostate cancers. Expression is further increased in higher-grade cancers and metastatic disease, and in hormone-refractory prostate cancers (Wright et al., 1995). PSMA is a type II membrane protein with a short N-terminal cytoplasmic tail and a large C-terminal extracellular domain (Israeli et al., 1993). The extracellular domain of PSMA has several potential N-glycosylation sites and shows homology (54% at nucleic acid level) to the transferrin receptor. PSMA is homologous to glutamate carboxypeptidase II (85% at nucleic acid level) and has been suggested to have folate hydrolase activity and N-acetylated alpha-linked acidic dipeptidase (NAALADase) activity (Pinto et al. 1996; Luthi-Carter et al., 1998). Abundance of PSMA expression in prostate cancer cells suggests that PSMA expression might be associated with events involved in prostate cancer progression (Rajasekaran et al.,2005).
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2009
- Accession Number
- ADA560904
Entities
People
- Ayyappan Rajasekaran
Organizations
- Nemours Children's Hospital, Delaware